Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round. The round includes new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines, and participation from existing investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.
Terremoto Biosciences Appoints James Christensen, Ph.D., as President and Head of Research & Development
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer. Dr. Baum succeeds Peter Thompson, M.D., who will continue to serve as Terremoto’s Board chairperson.
Terremoto Biosciences Closes $175 Million Series B Financing
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round. The round includes new investors EcoR1 Capital, Novo Holdings and Cormorant Capital, among others, and participation from existing investors OrbiMed and Third Rock Ventures.
Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing. The round was co-led by OrbiMed and Third Rock Ventures. Proceeds from the financing will be used to advance Terremoto’s lysine-targeted covalency platform and develop best-in-class therapies against known drug targets, as well as first-in-class medicines against the previously undruggable.
